{"abstract":"This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to Aura BioSciences to practice the inventions embodied in U.S. Provisional Patent Application No. 60/928,495 entitled, \"Papillomavirus Pseudoviruses for Detection and Therapy of Tumors\" filed May 8, 2007 [HHS Ref. No. E-186-2007/0-US-01], U.S. Provisional Patent Application No. 61/065,897 entitled \"Papillomavirus Pseudoviruses for Detection and Therapy of Tumors\" filed February 14, 2008 [HHS Ref. No. E-186-2007/1-US-01], PCT Application No. PCT/US2008/ 062296 \"Papillomavirus Pseudoviruses for Detection and Therapy of Tumors\" filed May 1, 2008 [HHS Ref. No. E-186-2007/2-PCT-01], Australian Patent Application No. 2008251615 entitled \"Papillomavirus Pseudoviruses for Detection and Therapy of Tumors\" filed May 1, 2008 [HHS Ref. No. E-186-2007/2-AU-02], Canadian Patent Application No. 2,686,990 entitled \"Papillomavirus Pseudoviruses for Detection and Therapy of Tumors\" filed May 1, 2008 [HHS Ref. No. E-186-2007/2-CA- 03], European Patent Application No. 08747407.8 entitled \"Papillomavirus Pseudoviruses for Detection and Therapy of Tumors\" filed May 1, 2008 [HHS Ref. No. E-186-2007/2-EP-04], U.S. Patent Application No. 12/598,684 entitled, \"Papillomavirus Pseudoviruses for Detection and Therapy of Tumors\" filed February 8, 2010 [HHS Ref. No. E-186-2007/2-US-05], and US Patent Application No. 13/763,365 entitled, \"Papilloma Pseudovirus for Detection and Therapy of Tumors\" filed February 8, 2013 [HHS Ref. No. E-186-2007/2-US-06] and all continuing applications and foreign counterparts. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide and the field of use may be limited to the development and use of the Licensed Patent Rights in combination with Licensee's proprietary nanosphere encapsulation technology for the treatment, diagnosis and imaging of cancer tumors and metastases as well as their respective pre-cursor dysplasia states. Licensee's proprietary nanosphere encapsulation technology is understood to consist of: (1) Methods for manipulating the outer proteins of human papillomavirus-derived nanoparticles to create particles targeted to solid tumors and distant metastases; and (2) enhancements for the delivery of particles created by Licensee's proprietary technology.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2013/03/26/2013-06837.html","cfr_references":[],"citation":"78 FR 18359","comment_url":null,"comments_close_on":"2013-04-25","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 25, 2013 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2013-06837","effective_on":null,"end_page":18360,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2013/03/26/2013-06837.xml","html_url":"https://www.federalregister.gov/documents/2013/03/26/2013-06837/prospective-grant-of-exclusive-license-papilloma-pseudovirus-and-virus-like-particles-as-a-delivery","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2013-06837?publication_date=2013-03-26","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2013-03-26/2013-06837/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":73,"last_updated":"2026-07-28 00:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2013-03-26/pdf/2013-06837.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2013-06837.pdf?1364216231","publication_date":"2013-03-26","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2013/03/26/2013-06837.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=NIH_FRDOC_0001","supporting_documents_count":0,"docket_id":"NIH_FRDOC_0001","regulation_id_number":null,"title":"Recently Posted NIH Rules and Notices.","checked_regulationsdotgov_at":"2013-04-27T05:01:20Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":18359,"subtype":null,"title":"Prospective Grant of Exclusive License: Papilloma Pseudovirus and Virus-Like Particles as a Delivery System for Human Cancer Therapeutics and Diagnostics","toc_doc":"Papilloma Pseudovirus and Virus-like Particles as a Delivery System for Human Cancer Therapeutics and Diagnostics","toc_subject":"Prospective Grant of Exclusive License:","topics":[],"type":"Notice","volume":78}